43results about "Disease diagnosis" patented technology

It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.

The present disclosure relates to a biosensor capable of measuring the total concentration of one or a plurality of amino acids with the use of a reaction surface comprising one or a plurality of metabolic enzymes or functional fragments thereof, but wherein the reaction surface does not comprise an electrode or electrically conductive support. In some embodiments, the biosensor comprises use of a thermophilic bacterial metabolic enzyme immobilized or attached to the reaction surface.

The present invention relates to a layered cell sorted tissue that is formed in vitro. The tissue is generated by the spontaneous sorting of cells from a homogenous cell mixture into discrete layers by cell type. Connective tissue components, such as fibronectin, may be used to manipulate orientation of the layers during the cell sorting process. The layered cell sorted tissue may be used as a skin graft for bums, wounds, and ulcers. The tissue may also be used in assays to determine effects of chemicals or drugs on human tissue in vitro as well as provide an in vitro assay for tumor cell metastasis.

The present application relates to methods for determining the occurrence of a liver disease in a subject by particular polypeptides biomarkers, and to kits using such biomarkers.

This invention concerns a method for the assessment of bone fragility and fracture risk, or osteoporosis, in a person. In said method, the concentration of gamma-carboxylated osteocalcin (COC) and optionally also the concentration of intact or total osteocalcin (IOC or TOC, respectively) in a body fluid sample of said person is measured. The concentration of gamma-carboxylated osteocalcin (COC) so obtained is compared to the mean concentration of gamma-carboxylated osteocalcin (mean COC) in similar body fluid samples of the population of the same age and sex. Alternatively, the determined ratio COC/IOC or COC/TOC for said person, is compared to the mean ratio COC/IOC or COC/TOC, (mean ratio COC/IOC or mean ratio COC/TOC) determined from measurements in similar body fluid samples of the population of the same age and sex. A measured COC that is lower than the mean COC is used as indication of osteoporosis, bone fragility or increased risk of bone fracture in said person. Preferably, a determined ratio COC/TOC that is lower than the mean ratio COC/TOC is used as indication of osteoporosis, bone fragility or increased risk of bone fracture in said person. The invention concerns further kits for use in the assessment according to this invention.

Antibodies which specifically bind to components of the DNA synthesome which are altered in malignant cells are disclosed. These antibodies can be used, inter alia, to diagnose, prognoses, and treat malignancy and in assays to screen cells, tissues, and body fluids for the presence of a malignant phenotype. These antibodies can be further used to identify test compounds having the ability to suppress the malignant phenotype in a cell by assaying for the ability to inhibit or block the function of an altered component of the DNA synthesome associated with the malignant phenotype. Further, disclosed herein are methods and kit for minimally invasively detecting the presence of neoplasms and malignant conditions using easily obtainable body fluids, such as blood, plasma, lymph, pleural fluid, spinal fluid, saliva, sputum, urine, and semen, for example, to both detect the presence of cancer as well as assess the stage of the disease and the prognosis of the patient. By detecting the presence of an altered form of a component of the DNA synthesome in body fluid, one can diagnose and prognose malignancy. The disclosed method and kit therefor can be used as a diagnostic biomarker for malignancy as well as a means of monitoring the progress and effectiveness of therapeutics.

The present invention relates to a method for determining whether a candidate human transplant donor is at risk of inducing acute graft versus host disease (aGVHD) in a human transplant recipient, which may in turn allow the selection of a donor exhibiting no risk for the recipient. The present invention also relates to a method for adjusting the immunosuppressive treatment administered to a human transplanted recipient following its graft transplantation after having performing the method for determining risk of the invention. The methods comprise expanding the candidate donor's iNKT cells (invariant NKT cells) and determining the presence or absence of expansion of the CD4(−) iNKT cell sub-population. In particular, CD3+CD4− TCRV[alpha]24V[beta]11 cells are determined. Kits are disclosed.

The invention discloses a kit for detecting the content of a KAPPA light chain.The kit comprises a reagent R1, a reagent R2 and a KAPPA light chain calibration material, wherein the reagent R1 comprises a first buffer solution, a first electrolyte, a surface active agent, a first stabilizer, a macromolecule accelerant and a first preservative, the reagent R2 comprises a second buffer solution, an anti-human KAPPA light chain antibody, a second electrolyte, a second stabilizer and a second preservative, and the C1 inhibitor calibration material comprises a third buffer solution, a third stabilizer, a third preservative, an antioxidant and a KAPPA light chain antigen.The invention further discloses the application of the kit for detecting the content of the KAPPA light chain and a method for detecting the content of the KAPPA light chain using the kit.By the adoption of the kit and the detection method, the content of the KAPPA light chain can be detected easily and quickly.

An immunological measurement is performed using anti-CTP antibody characterized by recognizing an antigenic determinant included in the polypeptide represented by amino acid numbers 118-132 of SEQ ID NO: 1, and reacting with native Cochlin-tomoprotein (CTP).

The invention relates to the technical field of biology, and in particular, relates to a kit for jointly detecting three rheumatism items and a preparation method of the kit. The bottom of a clampingshell is provided with a bottom plate; an NC membrane is arranged in the middle of the bottom plate; a combination pad is arranged at the end part of the left side of the NC membrane; a sample pad ismounted on the left side of the combination pad; a water absorption pad is arranged at the end part of the left side of the NC membrane; an RF detection line, an ASO detection line, a CRP detection line and a quality control line are sequentially arranged on the NC membrane; a sample adding hole and an observation opening are formed in the upper surface of the clamping shell; the preparation process of the kit comprises the steps: carrying out proportioning reaction on a coating solution, a confining liquid, a microsphere resuspension and a combination pad treatment liquid, then carrying out microsphere activation and related latex treatment, and then carrying out related region spraying and other multi-step treatment to finally complete the preparation process. According to the technicalscheme, the kit for joint detection of three rheumatism items and the preparation method thereof can simultaneously detect multiple types of rheumatism items, are high in detection efficiency, simpleto operate and easy for result observation and identification.

A previously unknown T cell receptor (TCR) activation pathway dependent on the aryl hydrocarbon receptor conferring resistance to calcineurin inhibitors and mTOR inhibitors is disclosed, including application of this pathway to the diagnosis and treatment of certain disease states refractory to treatment with calcineurin inhibitors. This alternative TCR activation pathway uniquely exists in a subset of CD8 T cells expanded in the setting of chronic rejection or rheumatoid arthritis. Expansion of this newly discovered calcineurin and mTOR inhibitor resistant CD8 T cell subset in humans can be quantified by measuring levels of certain biomarkers in the circulating CD8 T cell pool, such as Pla2g4a, to diagnose disease states mediated thereby. Additionally, methods for diagnosing ongoing active inflammation mediated by this resistant CD8 T cell subset in either chronic rejection or rheumatoid arthritis are provided, which comprise measuring levels of the biomarker Scin in the circulating CD8 T cell pool.

The invention relates to an electrochemical immunosensor of an electroactive substance modified MOF composite material as well as preparation and application of the electrochemical immunosensor. According to the electrochemical immunosensor, a Cu < 2 + > modified metal-organic framework composite material and a [Fe (CN) 6] < 3-> modified metal-organic framework composite material are used as signal tags for simultaneously detecting multiple components; and the immunosensor platform is prepared from the Au/rGO composite material. The electrochemical immunosensor provided by the invention has the advantages of wide linear range, high sensitivity, good selectivity, greenness, simplicity and the like, provides an effective method for simultaneously detecting two biomarkers of acute myocardial infarction (AMI) in clinical serum, has certain application potential in the aspect of early accurate diagnosis of AMI, and has a bright application prospect; and the method has enlightening significance on detection of other related biomarkers.

The invention discloses a detection method of an antiphospholipid syndrome related antibody. The detection method combines a microsphere analysis technology and a flow analysis technology, and performs joint detection on 12 antiphospholipid antibody indexes such as aCL-IgG, aCL-IgM, aCL-IgA, beta2-GPI-IgG, beta2-GPI-IgM, beta2-GPI-IgA, PS-IgM, PS-IgG, PI-IgM, PI-IgG, PI-IgM, PI-IgG and the like. The detection method comprises the following steps of: 1) preparing a serum sample; 2) preparing and activating microspheres; 3) preparing a capture antibody; 4) carrying out coupling; 5) performing antigen-antibody combination; 6) carrying out fluorescence labeling reaction; and 7) performing flow type detection. Compared with an existing conventional clinical detection method, the detection method has the advantages that joint detection of 12 antiphospholipid marker antibody indexes for diagnosing the anti-phospholipid syndrome is realized, the required sample size is smaller, the operation time is shorter, multi-parameter analysis can be performed, meanwhile, the specificity and the sensitivity are further extremely high, and the detection level and the standardization degree of the anti-phospholipid antibody index are further improved.

An assay system designed to detect a protein biomarker in urine that is diagnostic for interstitial cystitis (IC). The presence of a 9 amino acid glycopeptide, antiproliferative factor (APF), in urine is unique to patients with IC. Urine samples from patients who exhibit symptoms consistent with IC are added to the assay system. Binding of APF to the cytoskeletal associated protein 4 (CKAP4) is positive for the presence of APF in urine and diagnostic for IC. The diagnostic system is a significant and surprising advance in diagnosis of IC and has commercial applications relevant to women and men who suffer from symptoms consistent with IC.

The present invention relates to a method of diagnosing if a subject which has suffered from an acute myocardial infarction is also suffering from a pre-existing myocardial dysfunction, the method comprising a) determining the amount of a natriuretic peptide in a sample of the subject; b) determining the amount of a cardiac troponin in a sample of the subject; c) calculating the ratio (natriuretic peptide/cardiac troponin); and d) diagnosing if the elevated natriuretic peptide level is related to a preexisting myocardial dysfunction or if the elevated level is caused by the acute myocardial infarction, based on the ratio calculated in step c). The method allows determining whether the individual has suffered from a myocardial dysfunction, in particular heart failure, before the myocardial infarction has occurred.

The invention relates to the use of tissue specific transcription factor-nucleosome adducts or transcription cofactor-nucleosome adducts as biomarkers in a biological fluid for the detection or diagnosis of a cancer in a subject. The invention further relates to using said tissue specific transcription factor or cofactor adducts to identify the site of development of a cancer in a subject.

The invention discloses a preparation method and application of a fluorescent reagent strip for quantitatively detecting the concentration of ProAKAP4, and belongs to the field of in-vitro diagnostic reagents; a fluorescence immunochromatography technology is introduced into the detection of proAKAP4, and the prepared immunochromatography test strip for proAKAP4 adopts a double-antibody sandwich method; a proAKAP4 antigen in a sample pad is combined with a proAKAP4 antibody marked by fluorescent microspheres on a marking pad under the chromatographic action to form a compound, the compound moves to a detection line of a coating film under the chromatographic action, and the detection line of the coating film is coated with an antibody for identifying the other epitope of the proAKAP4 antigen to form a double-antibody sandwich compound; proAKAP4 with the concentration as low as 0.1 ng/mL in a seminal fluid sample can be detected, a detection result can be read through an immunofluorescence analyzer, professional operators are not needed, single-person quantitative detection of proAKAP4 is achieved, and the kit has the advantages of being convenient and rapid to use, easy to operate, high in sensitivity, easy to operate, low in detection cost and the like.

The invention belongs to the technical field of oligoasthenozoospermia and asthenozoospermia diagnosis, and particularly relates to application of MYH9 in preparation of a diagnostic reagent for severe oligoasthenozoospermia and asthenozoospermia. On the basis of a proteomics method, protein data in normal and severe oligoasthenozoospermia and asthenozoospermia samples are analyzed, and the protein abundance in the samples is detected by taking BSA protein signal intensity as a standard to obtain differential protein in normal and diseased samples. The MYH9 is detected and confirmed to be significantly up-regulated in severe oligoasthenozoospermia and asthenozoospermia samples through the method, has good credibility, is expected to be used as a detection marker of severe oligoasthenozoospermia and asthenozoospermia, and is applied to development of related detection reagents and kits.

Disclosed is a method for assisting a diagnosis of a risk of progression to nephropathy, the method including the steps of: measuring a concentration of apolipoprotein A1 (ApoA1) in urine of a diabetes patient who is at pre-nephropathy; and determining that the patient is at a high risk of progression to nephropathy when a value of the concentration of ApoA1 in urine is equal to or higher than a predetermined threshold value or determining that the patient is at a low risk of progression to nephropathy when the value of the concentration of ApoA1 in urine is lower than the predetermined threshold value.

The invention discloses a drainage type kit for early diagnosis of diabetic nephropathy, which comprises a kit body, a constant temperature block is fixedly connected in the kit body, the inner wall of the kit body is connected with a plurality of circularly distributed isolation detection components, and the isolation detection components can be separated and detected through the cooperation of the constant temperature block and a negative pressure drainage component. The sealing detection mode can be effectively achieved, serum in the serum storage tank can make contact with the sealed isolation detection assembly for detection under drainage of the negative pressure drainage assembly, it is effectively avoided that the serum and detection test paper are exposed to the external environment in the detection process, the detection error is reduced, and the reliability of the detection result is improved; the detection steps are effectively simplified, the detection difficulty is reduced, the kit is convenient for common personnel to operate and use, and the popularization of the kit body is effectively promoted.